secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sarepta Therapeutics, Inc. (SRPT)
CIK:        0000873303
Form:       8-K
Filed at:   2024-11-26T23:59:59+00:00
Accession:  0001193125-24-265627
Event type: m_and_a
Sentiment:  positive
Materiality: 0.90
Item codes: 1.01, 5.02, 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Sarepta enters $500M upfront license deal with Arrowhead for siRNA therapies; GC resigns
--------------------------------------------------------------------------------

- $500M upfront cash to Arrowhead; up to $300M near-term payments; up to $180M per program development milestones, $700M per program sales milestones; tiered royalties up to low double digits.
- Sarepta purchases 11.9M shares of Arrowhead for $325M in a private placement, with 180-day lock-up and standstill for up to 5 years.
- Programs include clinical siRNA candidates for FSHD, DM1, ataxias, IPF, and pre-clinical for Huntington's; Sarepta can select six additional discovery targets.
- Arrowhead leads initial development and manufacturing; Sarepta assumes responsibility at transition points and holds global commercialization rights.
- EVP Chief General Counsel Ryan Brown resigns effective Nov 26; Cristin Rothfuss named successor as EVP General Counsel.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/873303/000119312524265627/0001193125-24-265627-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/873303/000119312524265627/d856104d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-265627

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer